SIRT6 Activator: Natural Compounds, Synthetic Drugs & Human Evidence

A SIRT6 activator is an intervention that increases SIRT6 catalytic activity. That definition is narrower than much of the supplement marketing around the term. Raising SIRT6 gene expression, stabilizing the protein, increasing NAD+, and directly binding an allosteric site can all increase SIRT6 signaling—but they are not the same mechanism and should not be given the same evidence label.

The 2026 SIRT6 activator field now spans endogenous regulators, natural-product leads, selective research compounds and a clinical-stage drug. The key editorial job is to separate direct activation from indirect pathway support and to separate biochemical potency from human efficacy.

Class	Examples	What is established?	Human SIRT6-targeted evidence?
Endogenous/physiological regulators	Lamin A, long-chain fatty acids, post-translational regulation	Mechanistic activation/modulation	Not therapeutic trials
Natural compounds	Cyanidin, selected fucoidans, some flavonoids	Purified-enzyme/cell evidence; selected animal studies	Fucoidan aging studies ongoing
Synthetic research activators	UBCS039, MDL-800, MDL-801/811	Structural, cellular and animal pharmacology	No established human aging efficacy
Clinical-stage direct activator	Forvisirvat / SP-624	Human Phase 1/2 drug development	Yes, for psychiatric indications

What counts as direct SIRT6 activation?

The cleanest evidence is a purified-enzyme or structural experiment showing that a molecule binds SIRT6 and increases a defined catalytic reaction. Stronger cellular evidence then shows expected substrate changes—such as altered H3K9ac or H3K56ac—and ideally demonstrates that the effect weakens when SIRT6 is knocked down or knocked out.

Expression data alone are different. A compound can increase SIRT6 mRNA or protein without binding the enzyme. Likewise, an NAD+ precursor can increase the availability of a shared co-substrate used by multiple sirtuins and PARPs without selectively activating SIRT6.

How can SIRT6 be activated inside cells?

Physiological regulation

Long-chain fatty acids can stimulate SIRT6 deacetylation through its hydrophobic acyl-binding pocket [1]. SIRT6 activity is also influenced by protein interactions, localization, phosphorylation, ubiquitination and other post-translational modifications.

This is important because SIRT6 is not an isolated molecular switch. Its activity depends on where it is, what substrate it encounters, which catalytic function is being measured and what regulatory proteins are present.

Natural SIRT6 activators

Cyanidin

Cyanidin produced one of the largest activation signals in a natural-polyphenol SIRT6 screen—up to 55-fold in the reported biochemical assay [2]. That is useful target-discovery evidence, not a prediction that cyanidin-rich food will raise SIRT6 55-fold in a person.

Fucoidan

A 2017 brown-algae screen identified a highly purified fucoidan preparation as a potent SIRT6 activator [3]. Later 2025 preprints extended the story into SIRT6-dependent DNA repair, senescence and mouse lifespan/healthspan models.

There is an important literature-reconciliation issue here. Some secondary reviews have repeated conflicting classifications of fucoidan, but the primary 2017 activation experiment and later direct SIRT6 work support activation for the tested preparations. Because fucoidans vary by seaweed species, molecular weight, sulfation and extraction, the correct conclusion is not “all fucoidan activates SIRT6”; it is that specific fucoidan preparations have direct SIRT6-activation evidence.

See fucoidan as a SIRT6 activator for the ingredient-specific evidence.

Synthetic SIRT6 activators

UBCS039 and early structural activators

Structural studies showed that small molecules can occupy SIRT6-specific pockets and stimulate catalytic activity [4]. UBCS039 became a widely used probe for testing what happens when SIRT6 is pharmacologically increased in cells and animals.

MDL-800

MDL-800 is one of the best-characterized selective cellular activators. It increased SIRT6 deacetylase activity by up to 22-fold in the reported system, reduced H3K9ac/H3K56ac and produced SIRT6-dependent cellular effects [5].

MDL-800 is a research compound, not an approved anti-aging drug. A public GEO dataset titled “The SIRT6 Activator MDL-800 Extends Lifespan and Health-span of Mice” exists, but a repository dataset should not be treated as equivalent to a peer-reviewed lifespan publication. That evidence layer remains lower-confidence until a full peer-reviewed report is available.

Forvisirvat / SP-624

Forvisirvat is the translational outlier because it reached controlled human trials. Medicinal-chemistry work describes a brain-penetrant SIRT6 activator derived from a griseofulvin scaffold [6]. Related optimization work continues to refine this chemical family.

Why “fold activation” numbers are easy to misuse

SIRT6 activation depends heavily on assay design. A purified peptide assay is not a cell, a cell is not a tissue, and a tissue exposure is not a clinical outcome. Substrate identity, compound concentration, catalytic activity measured and binding mode can all change the apparent magnitude of activation.

A current medicinal-chemistry review therefore emphasizes selectivity, structure-activity relationships and drug-like behavior rather than ranking compounds by one headline fold-change number [7].

What is the strongest human evidence?

Forvisirvat provides the strongest direct human evidence that a designed SIRT6 activator can be administered orally. Published Phase 1 studies established short-term safety and pharmacokinetics [8]. A 319-person Phase 2 trial then tested 20 mg/day in major depressive disorder and did not significantly beat placebo on the prespecified primary endpoint overall [9].

That is clinically meaningful target validation, not longevity validation.

Fucoidan has a different human-development path. The branded SIRT6Activator is included at 2.4 g/day in the PROMETHEUS protocol, and a separate randomized healthy-aging study is testing 2.4 g/day against placebo. Those studies are important because they test a consumer-relevant natural activator, but standalone efficacy results are not yet available.

See SIRT6 clinical trials for registry status and study design.

Why activation is not always the desired direction

The newest pharmacology makes a simple “activate SIRT6 everywhere” model untenable. In some cancer models, activation suppresses growth; in intrahepatic cholangiocarcinoma, SIRT6 itself can drive tumor growth through glutamine metabolism [10]. In allergic airway inflammation, macrophage SIRT6 can promote inflammation, and inhibition was beneficial in the mouse model [11].

That is why modern SIRT6 drug development increasingly looks like context-specific modulation—activation in diseases characterized by insufficient SIRT6 activity, inhibition where SIRT6 supports pathology.

How should you evaluate a SIRT6 supplement?

• Exact ingredient: does the study use the same preparation, species or standardized extract?
• Directness: is SIRT6 activity measured, or is the claim inferred from a downstream pathway?
• Target dependence: does the effect disappear with SIRT6 knockdown/knockout?
• Exposure: is the concentration realistically achievable orally?
• Human translation: are there randomized human data for the same preparation and outcome?
• Context: does the target behave consistently in the tissue or disease relevant to the claim?

Bottom line

SIRT6 is a genuinely druggable enzyme. Natural and synthetic compounds can directly increase its catalytic activity, selective small-molecule programs have matured substantially, and one direct activator has reached human Phase 2 testing.

The unresolved question is not whether SIRT6 can be activated. It is when, where, how much and for which outcome activation is beneficial in humans.

For claimed outcomes, see SIRT6 activator benefits. For practical use, see dosage and safety.